Regulatory FDA weighs drug repurposing pathway for underserved diseases Pharmaceutical TechnologyApproved drugs could be expanded into disease areas with limited commercial potential, providing supporting data is available.Read full story pharminent May 12, 2026 (Last updated: May 16, 2026) Pharmaceutical Technology Approved drugs could be expanded into disease areas with limited commercial potential, providing supporting data is available. Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Pharma’s manufacturing reconfigurations provide CDMOs with expansion opportunitiesNext: A year after Vertex’s big launch, pain drug research faces a pivotal moment Related Stories Regulatory Outlook Therapeutics Secures FDA Approval for LYTENAVA pharminent July 31, 2026 Regulatory Outlook finally claims FDA approval for AMD drug pharminent July 27, 2026 Regulatory Outlook Therapeutics wins FDA approval for Lytenava in wet AMD pharminent July 27, 2026
